Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

COMMENT

JOURNAL ARTICLE

Does aspirin use reduce cardiovascular risk in diabetes?

John A Colwell

Nature Reviews. Endocrinology 2009, 5 (4): 188-90

The use of aspirin for the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus is controversial. According to the findings of a Japanese trial, aspirin does not reduce the risk of cardiovascular events in this group of patients, unless they are aged 65 years and above.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Hisao Ogawa, Masafumi Nakayama, Takeshi Morimoto, Shiro Uemura, Masao Kanauchi, Naofumi Doi, Hideaki Jinnouchi, Seigo Sugiyama, Yoshihiko Saito JAMA 2008 November 12, 300 (18): 2134-41

Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. Antonio Nicolucci JAMA 2008 November 12, 300 (18): 2180-1

[Primary prevention with aspirin for cardiovascular diseases in diabetic patients. What evidence supports the criteria of the ADA?]. Carmen Maciá Bobes, Aránzazu Ronzón Fernández, Elisa Fernández García Atencion Primaria 2007, 39 (3): 163-4

[Cardiovascular event in elderly patients with diabetes mellitus]. Kazushi Nomura Nihon Rinsho. Japanese Journal of Clinical Medicine 2013, 71 (11): 1954-9

Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. M A Bethel, P Harrison, H Sourij, Y Sun, L Tucker, I Kennedy, S White, L Hill, A Oulhaj, R L Coleman, R R Holman Diabetic Medicine: a Journal of the British Diabetic Association 2016, 33 (2): 224-30

Aspirin dose for prevention of cardiovascular disease in diabetics. Sandra N Nowak, Linda A Jaber Annals of Pharmacotherapy 2003, 37 (1): 116-21

Aspirin for primary prevention of cardiovascular events in people with diabetes. Michael Pignone, Mark J Alberts, John A Colwell, Mary Cushman, Silvio E Inzucchi, Debabrata Mukherjee, Robert S Rosenson, Craig D Williams, Peter W Wilson, M Sue Kirkman Journal of the American College of Cardiology 2010 June 22, 55 (25): 2878-86

[Finding the right platelet anti-aggregant prescription for type-2 diabetes patients, according to the ADA 2003 criteria]. Sandra Raméntol Teys, Vicenta Pujol Blaya, Mónica León de la Fuente, María León-Sanromà Atencion Primaria 2006 October 31, 38 (7): 413

[Acetylsalicylic acid in patients with diabetes for the primary prevention of cardiovascular disease]. M M C Hovens, S C Cannegieter Nederlands Tijdschrift Voor Geneeskunde 2004 October 16, 148 (42): 2097; author reply 2097-8

Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes? Robyn L Woods, Andrew M Tonkin, Mark R Nelson, Helena C Britt, Christopher M Reid Medical Journal of Australia 2009 June 1, 190 (11): 614-5

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Does aspirin use reduce cardiovascular risk in diabetes?

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips